-
2022-501458-13-01
4
2026-04-29
Advanced Stage of Classic Hodgkin Lymphoma
-
2025-521012-18-00
5
2026-04-13
Facioscapulohumeral Muscular Dystrophy (FSHD)
-
2025-522583-32-00
5
2026-04-13
Cold-Induced Urticaria and Symptomatic Dermographism
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2024-519344-32-00
9
2026-03-16
Non-small Cell Lung Cancer
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2024-517413-33-00
4
2026-02-03
Idiopathic Parkinson's Disease
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-516471-33-00
4
2026-01-19
Alport Syndrome
-
2025-521144-38-00
4
2025-12-23
Primary Central Nervous System Lymphoma
-
2022-500676-59-00
4
2025-12-18
EBV-positive nasopharyngeal carcinoma
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-522718-22-00
4
2025-12-16
Gastroesophageal Adenocarcinoma
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-515125-28-00
4
2025-12-08
Non-obstructive hypertrophic cardiomyopathy
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2024-517977-26-00
5
2025-11-25
acute decompensated heart failure
-
2025-521706-17-00
4
2025-11-25
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
-
2024-520219-42-00
10
2025-11-18
ivosidenib maintenance after SOC adjuvant chemotherapy in curative mID
-
2024-515979-35-00
5
2025-11-13
Generalized Myasthenia Gravis
-
2024-518008-33-00
5
2025-11-12
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis